What is KALA BIO, Inc.'s earnings per share (EPS)?

KALA BIO, Inc. (KALA) reported diluted earnings per share of -$3.31 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

KALA BIO, Inc. (KALA) Financials

KALA

FY2025 annual

Revenue $0 YoY not available

Net Income -$27.0M +29.9% YoY

EPS (Diluted) -$3.31 YoY not available

Operating Cash Flow -$32.0M -8.9% YoY

Market Cap $5.7M as of Oct 9, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.6x on $9.0M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 19, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KALA SEC filings page.

KALA BIO, Inc. (KALA) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KALA FY2025 2026-10-03

KALA’s reported economics remain development-stage: revenue shrank, R&D outweighed sales, and cash use exceeded accounting losses.

Between FY2021 and FY2022, revenue fell from $11.2M to $3.9M while R&D rose from $11.5M to $17.7M, showing that development spending dominated a shrinking commercial base rather than operating leverage emerging. Operating cash flow moved from -$108.2M to -$78.9M, but remained more negative than FY2022’s net loss, so cash conversion was weaker than reported earnings because noncash or working-capital effects widened the gap.

FY2022 SG&A was 16.7x revenue while R&D was 4.5x revenue, indicating that reported sales were not yet covering the expense structure required to operate and develop the business.

Debt-to-equity fell from 4.7x in FY2021 to 2.0x in FY2022, reducing leverage relative to the equity base. The current ratio stayed near 3.3x, yet operating cash flow remained negative, so balance-sheet liquidity did not represent internally funded operations.

Financial Health Signals

Financial health score not available

KALA BIO, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-113.87

KALA BIO, Inc. scores -113.87, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.7M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

KALA BIO, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

KALA BIO, Inc. reported a net loss of $27.0M while operations used $32.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

KALA BIO, Inc. reported an operating loss of $39.2M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$1.6M

YoY+85.8%

QoQ+2.5%

KALA BIO, Inc. reported -$1.6M in net income in Q2 2026. This represents an increase of 85.8% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.

EPS (Diluted)

-$21.32

KALA BIO, Inc. earned -$21.32 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$229K

YoY-99.3%

QoQ-87.0%

5Y CAGR-72.5%

10Y CAGR-42.8%

KALA BIO, Inc. held $229K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

19M

5Y CAGR-21.5%

KALA BIO, Inc. had 19M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-17.5%

QoQ-2.4pp

KALA BIO, Inc.'s ROE was -17.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 2.4 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$59K

YoY-99.1%

QoQ-3.3%

KALA BIO, Inc. invested $59K in research and development in Q2 2026. This represents a decrease of 99.1% from the same quarter a year earlier. Against the prior quarter it is down 3.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

KALA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KALA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	N/A	$0	$0	$0-100.0%	$3.9M-65.4%	$11.2M+76.7%	$6.4M+4.7%	$6.1M	N/A	$0	$0-100.0%	$45K
R&D Expenses	N/A	$18.8M-15.0%	$22.1M+18.9%	$18.6M+5.3%	$17.7M+53.3%	$11.5M-37.3%	$18.4M-32.7%	$27.3M-6.9%	$29.3M+1.0%	$29.0M+15.9%	$25.0M+119.9%	$11.4M
SG&A Expenses	N/A	$23.6M+28.8%	$18.3M-10.8%	$20.6M-68.4%	$65.0M-38.1%	$105.1M+29.6%	$81.1M+24.7%	$65.0M+83.5%	$35.4M+226.0%	$10.9M+42.2%	$7.6M+65.8%	$4.6M
Operating Income	N/A	-$39.2M+4.4%	-$41.0M-3.3%	-$39.7M+51.5%	-$81.7M+37.3%	-$130.2M-35.3%	-$96.2M-9.1%	-$88.2M-36.3%	-$64.7M-62.3%	-$39.9M-22.1%	-$32.7M-104.9%	-$15.9M
EBITDA	N/A	-$38.8M+4.6%	-$40.7M-3.5%	-$39.4M+51.5%	-$81.2M+37.2%	-$129.3M-35.6%	-$95.3M-9.1%	-$87.4M-35.8%	-$64.4M-62.6%	-$39.6M-22.3%	-$32.4M-107.3%	-$15.6M
Interest Expense	N/A	$3.3M-43.4%	$5.8M-0.5%	$5.8M-20.0%	$7.3M-13.3%	$8.4M-2.4%	$8.6M+1.3%	$8.5M+155.9%	$3.3M+225.2%	$1.0M+32.9%	$767K+27.0%	$604K
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	N/A	-$27.0M+29.9%	-$38.5M+8.7%	-$42.2M+5.9%	-$44.8M+68.6%	-$142.6M-36.7%	-$104.3M-10.6%	-$94.3M-41.4%	-$66.7M-58.1%	-$42.2M-27.3%	-$33.2M-98.8%	-$16.7M
EPS (Basic)	N/A	-$3.31+67.4%	-$10.15+41.5%	-$17.35+41.1%	-$29.48+72.8%	-$108.32-5343.2%	-$1.99	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$3.31	-$10.15	-$17.35	-$29.48	-$108.32	-$1.99	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	8M	4M	2M	2M	1M	52M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$59K-99.1%	$61K-99.0%	N/A	$6.1M+18.6%	$6.2M+17.2%	$6.1M-4.7%	N/A	$5.2M-6.9%
SG&A Expenses	$1.7M-64.2%	$1.7M-62.1%	N/A	$4.5M+3.0%	$4.6M+7.6%	$4.6M-15.3%	N/A	$4.4M-11.1%
Operating Income	-$1.7M+84.4%	-$1.8M+83.1%	N/A	-$7.2M+27.5%	-$11.0M-14.8%	-$10.7M+10.6%	N/A	-$10.0M-14.0%
EBITDA	N/A	N/A	N/A	-$7.1M+28.4%	-$11.0M-14.8%	-$10.6M+10.7%	N/A	-$9.9M-14.3%
Interest Expense	N/A	N/A	N/A	$963K-34.8%	$1.1M-25.9%	$1.1M-25.0%	N/A	$1.5M+1.3%
Net Income	-$1.6M+85.8%	-$1.6M+81.9%	N/A	-$7.6M+15.5%	-$11.2M-16.5%	-$8.9M+24.2%	N/A	-$8.9M-2.8%
EPS (Basic)	-$21.32+75.1%	-$0.14+99.8%	$0.86+158.5%	-$1.07+44.6%	-$85.64-2610.1%	-$70.49-1578.3%	-$1.47+50.8%	-$1.93+43.4%
EPS (Diluted)	-$21.32	-$0.14	$0.86	-$1.07	-$85.64	-$70.49	-$1.47	-$1.93
Diluted Shares (Avg)	74,159	12M	N/A	7M	130,262	126,917	N/A	5M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

KALA Balance Sheet

KALA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$9.5M-82.9%	$55.5M-0.8%	$55.9M-35.6%	$86.8M-37.7%	$139.4M-37.1%	$221.6M+43.6%	$154.3M-30.2%	$221.0M+89.6%	$116.5M+151.6%	$46.3M	N/A
Current Assets	$9.5M-82.0%	$52.8M-0.1%	$52.9M-38.5%	$85.9M-30.9%	$124.4M-27.4%	$171.4M+62.5%	$105.5M-40.4%	$177.0M+53.7%	$115.2M+152.5%	$45.6M	N/A
Cash & Equivalents	$7.6M-85.2%	$51.2M+0.6%	$50.9M-27.8%	$70.5M-23.5%	$92.1M+19.2%	$77.3M-9.6%	$85.4M-53.3%	$183.1M+59.6%	$114.7M+152.2%	$45.5M+689.6%	$5.8M
Short-Term Investments	$0	$0	$0	$0	$0-100.0%	$76.3M	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	$8.6M+65.2%	$5.2M+12.5%	$4.6M+13.5%	$4.1M	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$195K-98.7%	$15.3M+59.8%	$9.6M-16.9%	$11.6M	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.5M-94.2%	$43.2M-10.9%	$48.4M-28.6%	$67.8M-44.7%	$122.6M+0.8%	$121.6M-2.4%	$124.6M+7.5%	$116.0M+331.7%	$26.9M-80.0%	$134.1M	N/A
Current Liabilities	$2.5M-85.3%	$17.0M+103.2%	$8.3M-67.5%	$25.7M-31.4%	$37.4M+68.4%	$22.2M-10.3%	$24.8M+45.6%	$17.0M+14.4%	$14.9M+168.2%	$5.5M	N/A
Non-Current Liabilities	$0-100.0%	$26.2M-34.7%	$40.1M-4.9%	$42.2M-50.5%	$85.2M-14.3%	$99.4M-0.5%	$99.9M+0.9%	$99.0M+725.2%	$12.0M+18.1%	$10.2M	N/A
Long-Term Debt	N/A	$20.1M-41.2%	$34.2M-9.9%	$37.9M-51.9%	$78.9M+9.3%	$72.2M+1.5%	$71.2M+1.4%	$70.2M+485.9%	$12.0M+31.8%	$9.1M	N/A
Total Equity	$7.0M-43.3%	$12.3M+64.3%	$7.5M-60.5%	$19.0M+12.9%	$16.8M-83.2%	$100.0M+236.8%	$29.7M-71.7%	$105.0M+17.1%	$89.7M+202.2%	-$87.8M-54.9%	-$56.7M
Retained Earnings	-$694.9M-4.0%	-$667.9M-6.1%	-$629.4M-7.2%	-$587.2M-8.3%	-$542.4M-35.7%	-$399.8M-35.3%	-$295.5M-46.9%	-$201.1M-49.7%	-$134.4M-45.8%	-$92.1M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$10.6M-70.6%	$12.3M-74.5%	$9.5M-82.9%	$25.0M-53.7%	$36.1M-41.5%	$48.3M-9.0%	$55.5M-0.8%	$54.1M-11.5%
Current Assets	$10.6M-68.6%	$12.3M-73.1%	$9.5M-82.0%	$24.3M-52.7%	$33.7M-42.8%	$45.7M-8.7%	$52.8M-0.1%	$51.3M-11.4%
Cash & Equivalents	$229K-99.3%	$1.8M-95.8%	$7.6M-85.2%	$21.1M-57.1%	$31.9M-41.1%	$42.2M-12.9%	$51.2M+0.6%	$49.2M-12.2%
Short-Term Investments	$7.0M	$7.0M	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.5M-96.1%	$1.6M-96.3%	$2.5M-94.2%	$33.7M-28.7%	$39.3M-18.0%	$42.5M-8.3%	$43.2M-10.9%	$47.2M-5.4%
Current Liabilities	$1.5M-90.4%	$1.6M-93.2%	$2.5M-85.3%	$32.6M+36.5%	$16.0M-16.5%	$23.0M+93.4%	$17.0M+103.2%	$23.9M+131.7%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$0-100.0%	$1.1M-95.2%	$23.2M-19.0%	$19.6M-43.3%	$26.2M-34.7%	$23.4M-41.0%
Long-Term Debt	N/A	N/A	N/A	$26.9M+57.0%	$18.8M-17.7%	$15.1M-47.0%	$20.1M-41.2%	$17.2M-49.3%
Total Equity	$9.0M+382.1%	$10.8M+88.5%	$7.0M-43.3%	-$8.7M-226.3%	-$3.2M-123.4%	$5.7M-14.3%	$12.3M+64.3%	$6.9M-38.9%
Retained Earnings	-$698.1M-1.5%	-$696.5M-2.9%	-$694.9M-4.0%	-$695.6M-5.4%	-$688.0M-5.7%	-$676.9M-5.6%	-$667.9M-6.1%	-$659.7M-6.3%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

KALA Cash Flow Statement

KALA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$19.9M	-$32.0M-8.9%	-$29.4M-5.2%	-$27.9M+64.6%	-$78.9M+27.1%	-$108.2M-19.3%	-$90.7M+2.2%	-$92.7M-71.3%	-$54.1M-58.7%	-$34.1M-24.7%	-$27.3M-81.2%	-$15.1M
Depreciation & Amortization	N/A	$317K+22.4%	$259K-14.5%	$303K-43.6%	$537K-44.9%	$975K+6.9%	$912K+8.2%	$843K+139.5%	$352K+22.6%	$287K-3.4%	$297K-10.0%	$330K
Stock-Based Compensation	N/A	$7.0M-16.6%	$8.4M+12.4%	$7.5M+6.5%	$7.0M-56.4%	$16.1M+20.9%	$13.3M+33.2%	$10.0M+16.0%	$8.6M+141.2%	$3.6M+72.6%	$2.1M+224.3%	$638K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.3M-15.4%	$1.6M+228.8%	$480K+213.7%	$153K-39.3%	$252K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$94.1M-68.9%	-$55.7M-61.1%	-$34.6M-25.7%	-$27.5M-79.3%	-$15.3M
Investing Cash Flow	-$7.0M	-$15K+92.8%	-$208K+51.5%	-$429K-100.7%	$62.7M-11.4%	$70.8M+190.5%	-$78.2M-5758.4%	-$1.3M+15.4%	-$1.6M-228.8%	-$480K-213.7%	-$153K+39.3%	-$252K
Financing Cash Flow	-$4.9M	-$11.6M-138.9%	$29.9M+251.2%	$8.5M+207.1%	-$7.9M-118.7%	$42.6M-73.5%	$160.6M+1688.3%	$9.0M-92.8%	$124.1M+19.7%	$103.7M+54.3%	$67.2M+541.4%	$10.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.5M+90.7%	-$2.9M+67.2%	-$4.6M+0.9%	-$10.9M-130.2%	-$16.6M-79.7%	-$8.8M+18.6%	-$4.6M+40.3%	-$4.7M-60.1%
Depreciation & Amortization	N/A	N/A	$54K-21.7%	$128K+103.2%	$67K+9.8%	$68K+3.0%	$69K-1.4%	$63K-20.3%
Stock-Based Compensation	-$136K-106.1%	-$471K-120.4%	N/A	$2.0M+0.4%	$2.2M+19.0%	$2.3M-2.8%	N/A	$2.0M-15.3%
Investing Cash Flow	$0	-$7.0M	$0+100.0%	$1K+101.1%	N/A	N/A	-$69K-885.7%	-$90K-100.9%
Financing Cash Flow	$0+100.0%	$4.1M+3138.5%	-$9.0M-235.2%	$30K+116.7%	-$2.5M-116.9%	-$135K-101.6%	$6.6M+162.2%	-$180K-550.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

KALA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KALA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Margin	N/A	N/A	N/A	-2099.3%	-1158.8%	-1512.6%	-1452.5%	N/A	N/A	N/A	-35435.6%
Net Margin	N/A	N/A	N/A	-1151.6%	-1268.7%	-1639.8%	-1553.3%	N/A	N/A	N/A	-37071.1%
Return on Equity	-385.6%-73.4pp	-312.3%+250.1pp	-562.4%-326.1pp	-236.2%+612.4pp	-848.6%-744.3pp	-104.3%+213.4pp	-317.8%-254.2pp	-63.6%-16.5pp	-47.1%	N/A	N/A
Return on Assets	-284.3%-214.9pp	-69.4%+6.0pp	-75.4%-23.8pp	-51.6%+50.6pp	-102.3%-55.2pp	-47.1%+14.1pp	-61.1%-30.9pp	-30.2%+6.0pp	-36.2%+35.4pp	-71.6%	N/A
Current Ratio	3.81+0.7x	3.11-3.2x	6.33+3.0x	3.350.0x	3.32-4.4x	7.71+3.5x	4.26-6.1x	10.41+2.7x	7.75-0.5x	8.23	N/A
Debt-to-Equity	0.36-1.3x	1.63-2.9x	4.56+2.6x	2.00-2.7x	4.70+4.0x	0.72-1.7x	2.40+1.7x	0.67+0.5x	0.13	N/A	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.040.0x	0.08+0.1x	0.030.0x	0.04	N/A	0.000.0x	0.00	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-1548.5%	N/A	N/A	N/A	-34091.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-17.5%	-15.1%+141.7pp	N/A	N/A	N/A	-156.7%+20.5pp	N/A	-130.5%-52.9pp
Return on Assets	-14.9%+16.0pp	-13.2%+5.4pp	N/A	-30.2%-13.7pp	-30.9%-15.4pp	-18.5%+3.7pp	N/A	-16.6%-2.3pp
Current Ratio	6.88+4.8x	7.91+5.9x	3.81+0.7x	0.75-1.4x	2.10-1.0x	1.99-2.2x	3.11-3.2x	2.15-3.5x
Debt-to-Equity	0.17	0.14-2.5x	0.36-1.3x	N/A	N/A	2.65-1.6x	1.63-2.9x	2.50-0.5x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
KALA BIO, Inc. KALA	FY2025	$0	-$27.0M	N/A	$5.7M	—
Biomea Fusion, Inc. BMEA	FY2025	N/A	-$61.8M	N/A	$102.9M	—
Corbus Pharmaceuticals Holdings, Inc. CRBP	FY2025	N/A	-$78.5M	N/A	$104.1M	—
Inhibikase Therapeutics, Inc. IKT	FY2025	N/A	-$48.3M	N/A	$274.9M	—
Protara Therapeutics, Inc. TARA	FY2025	N/A	-$57.4M	N/A	$162.8M	—
Equillium, Inc. EQ	FY2025	N/A	-$22.4M	N/A	$89.4M	—

Where KALA BIO, Inc. Ranks

Frequently Asked Questions

What is KALA BIO, Inc.'s annual revenue?

KALA BIO, Inc. (KALA) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is KALA BIO, Inc. profitable?

No, KALA BIO, Inc. (KALA) reported a net income of -$27.0M in fiscal year 2025.

What is KALA BIO, Inc.'s EBITDA?

KALA BIO, Inc. (KALA) had EBITDA of -$38.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is KALA BIO, Inc.'s return on equity (ROE)?

KALA BIO, Inc. (KALA) has a return on equity of -385.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is KALA BIO, Inc.'s operating cash flow?

KALA BIO, Inc. (KALA) recorded an outflow of $32.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are KALA BIO, Inc.'s total assets?

KALA BIO, Inc. (KALA) had $9.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does KALA BIO, Inc. spend on research and development?

KALA BIO, Inc. (KALA) invested $18.8M in research and development during fiscal year 2025.

How many shares does KALA BIO, Inc. have outstanding?

KALA BIO, Inc. (KALA) had 929M shares outstanding as of fiscal year 2025.

What is KALA BIO, Inc.'s current ratio?

KALA BIO, Inc. (KALA) had a current ratio of 3.81 as of fiscal year 2025, which is generally considered healthy.

What is KALA BIO, Inc.'s debt-to-equity ratio?

KALA BIO, Inc. (KALA) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is KALA BIO, Inc.'s return on assets (ROA)?

KALA BIO, Inc. (KALA) had a return on assets of -284.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is KALA BIO, Inc.'s P/E ratio?

KALA BIO, Inc. (KALA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $5.7M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is KALA BIO, Inc.'s price-to-sales ratio?

KALA BIO, Inc. (KALA) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $5.7M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does KALA BIO, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, KALA BIO, Inc. (KALA) held $7.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $32.0M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is KALA BIO, Inc.'s Altman Z-Score?

KALA BIO, Inc. (KALA) has an Altman Z-Score of -113.87, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is KALA BIO, Inc.'s Piotroski F-Score?

KALA BIO, Inc. (KALA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are KALA BIO, Inc.'s earnings high quality?

KALA BIO, Inc. (KALA) reported a net loss of $27.0M while operations used $32.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can KALA BIO, Inc. cover its interest payments?

KALA BIO, Inc. (KALA) reported an operating loss of $39.2M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.